Why Should Hydrocodone Combination Products Be Categorized as CII Drugs?

Published Online: Thursday, January 30, 2014
Follow Pharmacy_Times:
In this video, Mary Lynn McPherson, PharmD, professor and vice chair at the University of Maryland School of Pharmacy, explains why hydrocodone combination products should no longer be categorized as Schedule III drugs.
 
This is the eleventh in a series of videos in which Dr. McPherson argues in favor of categorizing hydrocodone combination products as Schedule II drugs, and Jeff Fudin, PharmD, argues against doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Aaron Steffenhagen, PharmD, BCPS, a clinical pharmacy manager at the University of Wisconsin Hospital, discusses measures of gauging stroke.
Ashley Huntsberry and Joselyn Benabe from the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences competed against a record number of participants to win the 19th annual ASHP National Clinical Skills Competition SM, held December 7, 2014, during the ASHP Midyear Clinical Meeting in Anaheim, CA.
Binita Patel, PharmD, MS, explains the role telehealth and telepharmacy will play in patient management.
Binita Patel, PharmD, MS, discusses how provider status would affect reimbursement models in ambulatory pharmacy.
Latest Issues
$auto_registration$